PSM Antibody (k1H7): sc-130546
- PSM Antibody (k1H7) is a mouse monoclonal IgG1, cited in 2 publications, provided at 50 µg/0.5 ml
- raised against amino acids 117-351 of PSM of human origin
- recommended for detection of PSM of mouse, rat and human origin by WB, IP and ELISA
- At present, we have not yet completed the identification of the preferred secondary detection reagent(s) for PSM Antibody (k1H7). This work is in progress.
QUICK LINKS
SEE ALSO...
PSM Antibody (k1H7) is a mouse monoclonal IgG1 antibody that detects prostate-specific membrane antigen (PSM) in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), and enzyme-linked immunosorbent assay (ELISA). Anti-PSM antibody (k1H7) recognizes an integral membrane protein that plays a crucial role in the progression of prostate cancer, as PSM is overexpressed in malignant tumors while remaining at low levels in normal tissues, making PSM a valuable biomarker for diagnosis and treatment monitoring. The unique structure of PSM, characterized by its ability to function as a folate hydrolase, allows PSM to facilitate the uptake of folate, which is essential for cell proliferation and survival, particularly in rapidly dividing cancer cells. This function underscores PSM′s importance not only as a diagnostic marker but also as a potential therapeutic target, as inhibiting PSM activity could disrupt the nutrient supply to tumors. PSM monoclonal antibody (k1H7) serves as an essential tool for researchers and clinicians aiming to better understand prostate cancer biology and improve patient outcomes through early detection and targeted therapies.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
PSM Antibody (k1H7) References:
- 99mTechnetium-based Prostate-specific Membrane Antigen-radioguided Surgery in Recurrent Prostate Cancer. | Maurer, T., et al. 2019. Eur Urol. 75: 659-666. PMID: 29625755
- Advances in Urologic Imaging: Prostate-Specific Membrane Antigen Ligand PET Imaging. | Hofman, MS., et al. 2018. Urol Clin North Am. 45: 503-524. PMID: 30031469
- Prostate-Specific Membrane Antigen Uptake and Survival in Metastatic Castration-Resistant Prostate Cancer. | Vlachostergios, PJ., et al. 2021. Front Oncol. 11: 630589. PMID: 33680970
- Immunohistochemical Reactivity of Prostate-Specific Membrane Antigen in Salivary Gland Tumors. | Nishida, H., et al. 2022. Head Neck Pathol. 16: 427-433. PMID: 34420181
- Prostate-Specific Membrane Antigen as Target for Neuroimaging of Central Nervous System Tumors. | Stopa, BM., et al. 2022. Mol Imaging. 2022: 5358545. PMID: 35517711
- Prostate-specific membrane antigen expression in intracranial lesions - a review of the primary, metastatic, and nonneoplastic lesions. | Pełka, K., et al. 2023. Nucl Med Rev Cent East Eur. 26: 134-142. PMID: 37987378
- Current Status of Prostate-specific Membrane Antigen-targeted Alpha Radioligand Therapy in Prostate Cancer. | Yamamichi, G., et al. 2024. Anticancer Res. 44: 879-888. PMID: 38423627
- Imaging and therapy in prostate cancer using prostate specific membrane antigen radioligands. | Naik, M., et al. 2024. Br J Radiol. 97: 1391-1404. PMID: 38733571
- Long-Term Outcomes of Prostate-Specific Membrane Antigen-PET Imaging of Recurrent Prostate Cancer. | Kunst, N., et al. 2024. JAMA Netw Open. 7: e2440591. PMID: 39441595
- Prostate-specific membrane antigen as target for vasculature-directed therapeutic strategies in solid tumors. | Puik, JR., et al. 2025. Crit Rev Oncol Hematol. 205: 104556. PMID: 39551117
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
PSM Antibody (k1H7) | sc-130546 | 50 µg/0.5 ml | $322.00 |